Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease

Inclusion Criteria

• •1. Adult patients aged 18 to 75 years.
• •2. Established diagnosis of Crohn's disease confirmed by radiologic, histologic, or endoscopic evidence.
• •3. Active Crohn's disease at screening, defined as a Crohn's Disease Activity Index (CDAI) score between 220 and 450 (inclusive).
• •4. Adequate cardiac, renal, and hepatic function, as assessed by the investigator based on screening laboratory tests, physical examination, and medical history, without findings that would pose an undue risk for study participation.
• •5. Willingness and ability to provide written informed consent.
• •6. Agreement to undergo all scheduled study procedures, including up to 3 endoscopic evaluations.